Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Millennium Management LLC

Millennium Management LLC lifted its position in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 13.5% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,842,063 shares of the biotechnology company's stock after purchasing an additional 218,518 shares during the quarter. Millennium Management LLC owned about 3.35% of Astria Therapeutics worth $16,763,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ATXS. Quest Partners LLC grew its stake in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after buying an additional 3,112 shares during the period. Ameritas Investment Partners Inc. grew its position in Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company's stock valued at $70,000 after acquiring an additional 2,861 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of Astria Therapeutics during the first quarter valued at approximately $200,000. Hsbc Holdings PLC acquired a new position in shares of Astria Therapeutics during the second quarter worth $171,000. Finally, American International Group Inc. boosted its stake in shares of Astria Therapeutics by 49.4% in the first quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company's stock valued at $346,000 after purchasing an additional 8,122 shares during the period. Institutional investors and hedge funds own 98.98% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on ATXS. Oppenheimer boosted their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an "outperform" rating in a report on Tuesday, August 13th. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Friday, September 27th. Wedbush reaffirmed an "outperform" rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. TD Cowen started coverage on Astria Therapeutics in a report on Monday, July 29th. They issued a "buy" rating and a $35.00 price target on the stock. Finally, Evercore ISI upgraded Astria Therapeutics to a "strong-buy" rating in a research report on Wednesday, August 14th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $25.20.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS traded up $0.56 on Friday, hitting $11.87. The company's stock had a trading volume of 241,200 shares, compared to its average volume of 676,491. The company has a market capitalization of $651.82 million, a price-to-earnings ratio of -5.12 and a beta of 0.71. Astria Therapeutics, Inc. has a 12 month low of $4.26 and a 12 month high of $16.90. The stock's 50-day moving average is $11.30 and its two-hundred day moving average is $10.69.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). Equities analysts expect that Astria Therapeutics, Inc. will post -1.66 earnings per share for the current fiscal year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.